Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.54 |
| ▸ | CA1 | P00915 | 10/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867142 | 0.86 | CA2 (0.52) | CA2CA1CA9PTGESCA12 | |
| SCHEMBL7047775 | 0.84 | PTGES (0.67) | CA2CA1CA9PTGESCA12 | |
| SCHEMBL6860325 | 0.79 | SLC16A3 (0.42) | PTGESSLC16A3FFAR1FFAR4HDAC1 | |
| SCHEMBL6860157 | 0.75 | CA2 (0.53) | CA2CA1CA9PTGESCA12 | |
| SCHEMBL6226263 | 0.75 | CA1 (0.75) | CA2CA1CA9CA12HDAC1 | |
| SCHEMBL6866180 | 0.73 | FFAR1 (0.58) | SLC16A3FFAR1FFAR4RAB9A | |
| SCHEMBL14106122 | 0.73 | CA1 (0.56) | CA2CA1CA9CA12MEN1 | |
| SCHEMBL18542656 | 0.71 | CA1 (0.65) | CA2CA1CA9CA12MEN1 | |
| SCHEMBL2775254 | 0.71 | CA1 (0.52) | CA2CA1CA9CA12MEN1 | |
| SCHEMBL6866357 | 0.70 | CA2 (0.51) | CA2CA1CA9PTGESCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812252-B2 | ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030181764-A1 | Acylsulfonamide derivatives | AJINOMOTO CO. INC (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1316548-A1 | ACYLSULFONAMIDE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181764-A1 | Acylsulfonamide derivatives | DPP4, SLC5A2, GLP1R | CA2 1724/4885CA1 3314/4885CA9 2289/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | CA2 831/4885CA1 2426/4885CA9 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.